

1653  
DPW

**STATEMENT UNDER 37 CFR 1.97(e) ACCOMPANYING  
INFORMATION DISCLOSURE STATEMENT**

Docket No.  
15004Z

In Re Application Of: Alan P. Kozikowski, et al.

FEB 18 2005

PATENTS TRADEMARKS  
EXAMINER

Application No. 09/246,307	Filing Date 2/8/1999	Customer No. 23389	Group Art Unit 1653	Confirmation No. 6016
-------------------------------	-------------------------	-----------------------	------------------------	--------------------------

Invention: **CYCLIC DIPEPTIDES AND AZETIDINONE COMPOUNDS AND THEIR USE IN TREATING CNS  
NEURODEGENERATIVE DISORDERS**

**COMMISSIONER FOR PATENTS:**

This is a statement under the provisions of 37 CFR 1.97(e) in the above-identified application.

Check applicable statement herebelow:

**Statement Under 37 CFR 1.97(e)(1)**

Each item of information contained in the accompanying Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the Information Disclosure Statement.

**Statement Under 37 CFR 1.97(e)(2)**

No item of information contained in the accompanying Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the undersigned person, after making reasonable inquiry, no item of information contained in the accompanying Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

  
Signature

Mark J. Cohen  
Registration No. 32,211  
Scully, Scott, Murphy & Presser  
400 Garden City, Suite 300  
Garden City, NY 11530  
(516) 742-4343


CC:

Dated: **February 15, 2005**

**Certificate of Mailing by First Class Mail**

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to "Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450" [37 CFR 1.8(a)] on


2/15/2005

  
(Date)  
Signature of Person Mailing Correspondence

Mark J. Cohen

Typed or Printed Name of Person Mailing Correspondence

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

**Applicants:** Alan P. Kozikowski, et al. 

**Examiner:** A. Gupta

**Serial No.:** 09/246,307

**Art Unit:** 1653

**Filed:** February 8, 1999

**Docket:** 15004Z

**For:** CYCLIC DIPEPTIDES AND  
AZETIDINONE COMPOUNDS AND  
THEIR USE IN TREATING CNS INJURY  
AND NEURODEGENERATIVE DISORDERS

**Dated:** February 15, 2005

**Confirmation No.:** 6016

Mailstop Amendment  
Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir:

In accordance with 37 C.F.R. §§1.97 and 1.98, it is requested that the following references, which are also listed on the attached Form PTO-1449, be made of record in the above-identified case.

1. Massimo Falorni, et al. "Chiral Ligands Containing Heteroatoms. 11.<sup>1</sup> Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaldehyde", Tetrahedron Asymmetry, Vol. 4, No. 11, pp. 2389-2398, (1993); and
2. Gamini S. Jayatilake, et al., "Metabolites from an Antarctic Sponge-Associated Bacterium, *Pseudomonas Aeruginosa*", J. Nat. Prod., Vol. 59, pp. 293-296, (1996).

**CERTIFICATE OF MAILING UNDER 37 C.F.R. §1.8(a)**


I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: February 15, 2005

  
\_\_\_\_\_  
Mark J. Cohen

The references were cited in a Supplementary Partial Search Report dated January 7, 2005, received from the European Patent Office. Applicants are submitting copies of the above-cited references, together with a copy of the Supplementary Partial Search Report. The relevance of the above-identified references has been described in the Supplementary Partial Search Report.

This Information Disclosure Statement is accompanied by a Statement under 37 C.F.R. §1.97(e) after the issuance of an Official Action, but before the issuance of a Final Rejection or Notice of Allowance. Inasmuch as these references were cited in a Search Report that issued within 3-months of the filing hereof and inasmuch as the Information Disclosure Statement is accompanied by a Statement in accordance with 37 C.F.R. § 1.97(e), no fee is required.

Respectfully submitted  
  
Mark J. Cohen  
Registration No. 32,211

Scully, Scott, Murphy & Presser  
400 Garden City Plaza, Suite 300  
Garden City, New York 11530  
Telephone: (516) 742-4343

MJC:ng

Form PTO-1449 (REV. 7-80) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		Atty. Docket No. (Optional)	Application Number			
<b>INFORMATION DISCLOSURE CITATION</b> <i>(Use several sheets if necessary)</i>		15004Z	09/246,307			
		Applicant(s) Alan P. Kozikowski, et al.				
		Filing Date February 8, 1999	Group Art Unit 1653			
		<b>U.S. PATENT DOCUMENTS</b>				
EXAMINER INITIAL*	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE (if appropriate)
<b>FOREIGN PATENT DOCUMENTS</b>						
REF	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
						YES
<b>OTHER DOCUMENTS</b> <i>(Including Author, Title, Date, Pertinent Pages, Etc.)</i>						
		Massimo Falorni, et al. "Chiral Ligands Containing Heteroatoms. 11. <sup>1</sup> Optically Active 2-Hydroxymethyl Piperazines as Catalysts in the Enantioselective Addition of Diethylzinc to Benzaldehyde", <u>Tetrahedron Asymmetry</u> , Vol. 4, No. 11, pp. 2389-2398, (1993)				
		Gamini S. Jayatilake, et al., "Metabolites from an Antarctic Sponge-Associated Bacterium, <u>Pseudomonas Aeruginosa</u> ", <u>J. Nat. Prod.</u> , Vol. 59, pp. 293-296, (1996)				
EXAMINER		DATE CONSIDERED				
<small>* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.</small>						